Turning-off signaling by siglecs, selectins, and galectins: Chemical inhibition of glycan-dependent interactions in cancer

Frontiers in Oncology

Volumn 6, Issue MAY, 2016, Pages

  Cagnoni, Alejandro J ^a   Pérez Sáez, Juan M ^a   Rabinovich, Gabriel A ^a,b   Mariño, Karina V ^a  

^a Consejo Nacional de Investigaciones Científicas y Técnicas ^*  (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

C type lectins; Cancer; Galectins; Glycans; Selectins; Siglecs

Indexed keywords

GALACTOMANNAN; GALAPTIN; GALECTIN; GLYCAN; GLYCOPEPTIDE; OLIGOSACCHARIDE; PECTIN; SELECTIN; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN;

CARCINOGENESIS; CELL COMMUNICATION; CELL INTERACTION; CELL INVASION; CLINICAL TRIAL (TOPIC); DNA METHYLATION; DRUG STRUCTURE; ENZYME INHIBITION; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; METASTASIS; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; STEREOCHEMISTRY;

EID: 84973573760     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00109     Document Type: Review

References (171)

1. Kissick HT, Sanda MG. The role of active vaccination in cancer immunotherapy: lessons from clinical trials. Curr Opin Immunol (2015) 35:15-22. doi:10.1016/j.coi.2015.05.004
2. Liu C-C, Ye X-S. Carbohydrate-based cancer vaccines: target cancer with sugar bullets. Glycoconj J (2012) 29(5-6):259-71. doi:10.1007/s10719-012-9399-9
3. Miller JFAP, Sadelain M. The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell (2015) 27(4):439-49. doi:10.1016/j.ccell.2015.03.007
4. Koster BD, de Gruijl TD, van den Eertwegh AJM. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. Curr Opin Oncol (2015) 27(6):482-8. doi:10.1097/cco.0000000000000221
5. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 515(7528):577-81. doi:10.1038/nature13988
6. Hart GW, Copeland RJ. Glycomics hits the big time. Cell (2010) 143(5):672-6. doi:10.1016/j.cell.2010.11.008
7. Corfield AP, Berry M. Glycan variation and evolution in the eukaryotes. Trends Biochem Sci (2015) 40(7):351-9. doi:10.1016/j.tibs.2015.04.004
8. Stanley P, Schachter H, Taniguchi N. N-Glycans. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors. Essentials of Glycobiology. 2nd edn, Chapter 8. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press (2009). Available from: http://www.ncbi.nlm.nih.gov/books/NBK1917/
9. Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer (2015) 15(9):540-55. doi:10.1038/nrc3982
10. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell (2006) 126(5):855-67. doi:10.1016/j.cell.2006.08.019
11. Mariño K, Saldova R, Adamczyk B, Rudd PM. Changes in serum N-glycosylation profiles: functional significance and potential for diagnostics. In: Rauter AP, Lindhorst TK, editors. Carbohydrate Chemistry. (Vol. 37). Cambridge: The Royal Society of Chemistrys (2012). p. 57-93
12. Reis CA, Osorio H, Silva L, Gomes C, David L. Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol (2010) 63(4):322-9. doi:10.1136/jcp.2009.071035
13. Peracaula R, Barrabás S, Sarrats A, Rudd PM, de Llorens R. Altered glycosylation in tumours focused to cancer diagnosis. Dis Markers (2008) 25(4-5):207-18. doi:10.1155/2008/797629
14. Häuselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis. Front Oncol (2014) 4:28. doi:10.3389/fonc.2014.00028
15. Christiansen MN, Chik J, Lee L, Anugraham M, Abrahams JL, Packer NH. Cell surface protein glycosylation in cancer. Proteomics (2014) 14(4-5):525-46. doi:10.1002/pmic.201300387
16. Daniotti JL, Vilcaes AA, Torres Demichelis V, Ruggiero FM, Rodriguez-Walker M. Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches. Front Oncol (2013) 3:306. doi:10.3389/fonc.2013.00306
17. Vasconcelos-dos-Santos A, Oliveira IA, Lucena MC, Mantuano NR, Whelan SA, Dias WB, et al. Biosynthetic machinery involved in aberrant glycosylation: promising targets for developing of drugs against cancer. Front Oncol (2015) 5:138. doi:10.3389/fonc.2015.00138
18. Brooks SA, Carter TM, Royle L, Harvey DJ, Fry SA, Kinch C, et al. Altered glycosylation of proteins in cancer: what is the potential for new anti-tumour strategies. Anticancer Agents Med Chem (2008) 8(1):2-21. doi:10.2174/187152008783330860
19. Boligan K, Mesa C, Fernandez L, von Gunten S. Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense. Cell Mol Life Sci (2015) 72(7):1231-48. doi:10.1007/s00018-014-1799-5
20. Mechref Y, Hu Y, Garcia A, Hussein A. Defining putative glycan cancer biomarkers by mass spectrometry. Bioanalysis (2012) 4(20):2457-69. doi:10.4155/bio.12.246
21. Harvey DJ, Merry AH, Royle L, Campbell MP, Dwek RA, Rudd PM. Proposal for a standard system for drawing structural diagrams of N-and O-linked carbohydrates and related compounds. Proteomics (2009) 9(15):3796-801. doi:10.1002/pmic.200900096
22. Patani N, Jiang W, Mokbel K. Prognostic utility of glycosyltransferase expression in breast cancer. Cancer Genomics Proteomics (2008) 5(6):333-40
23. Gomes J, Marcos NT, Berois N, Osinaga E, Magalhães A, Pinto-de-Sousa J, et al. Expression of UDP-N-acetyl-d-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma. J Histochem Cytochem (2009) 57(1):79-86. doi:10.1369/jhc.2008.952283
24. Berois N, Gattolliat C-H, Barrios E, Capandeguy L, Douc-Rasy S, Valteau-Couanet D, et al. GALNT9 gene expression is a prognostic marker in neuroblastoma patients. Clin Chem (2013) 59(1):225-33. doi:10.1373/clinchem.2012.192328
25. Chen Z, Gulzar ZG, St. Hill CA, Walcheck B, Brooks JD. Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers. Prostate (2014) 74(10):1059-67. doi:10.1002/pros.22826
26. Anugraham M, Jacob F, Nixdorf S, Everest-Dass AV, Heinzelmann-Schwarz V, Packer NH. Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status. Mol Cell Proteomics (2014) 13(9):2213-32. doi:10.1074/mcp.M113.037085
27. Wang Y, Fukuda T, Isaji T, Lu J, Im S, Hang Q, et al. Loss of a1,6-fucosyltransferase inhibits chemical-induced hepatocellular carcinoma and tumorigenesis by down-regulating several cell signaling pathways. FASEB J (2015) 29(8):3217-27. doi:10.1096/fj.15-270710
28. Chia J, Goh G, Bard F. Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives. Biochim Biophys Acta (2016). doi:10.1016/j.bbagen.2016.03.008
29. Taniguchi N, Kizuka Y. Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics. Adv Cancer Res (2015) 126:11-51. doi:10.1016/bs.acr.2014.11.001
30. Saldova R, Dempsey E, Pérez-Garay M, Mariño K, Watson JA, Blanco-Fernández A, et al. 5-AZA-2'-deoxycytidine induced demethylation influences N-glycosylation of secreted glycoproteins in ovarian cancer. Epigenetics (2011) 6(11):1362-72. doi:10.4161/epi.6.11.17977
31. Bassagañas S, Allende H, Cobler L, Ortiz MR, Llop E, de Bolós C, et al. Inflammatory cytokines regulate the expression of glycosyltransferases involved in the biosynthesis of tumor-associated sialylated glycans in pancreatic cancer cell lines. Cytokine (2015) 75(1):197-206. doi:10.1016/j.cyto.2015.04.006
32. Venkitachalam S, Revoredo L, Varadan V, Fecteau RE, Ravi L, Lutterbaugh J, et al. Biochemical and functional characterization of glycosylation-associated mutational landscapes in colon cancer. Sci Rep (2016) 6:23642. doi:10.1038/srep23642
33. Dimitroff CJ. Galectin-binding O-glycosylations as regulators of malignancy. Cancer Res (2015) 75(16):3195-202. doi:10.1158/0008-5472.CAN-15-0834
34. Croci DO, Cerliani JP, Dalotto-Moreno T, Mendez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell (2014) 156(4):744-58. doi:10.1016/j.cell.2014.01.043
35. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol (2007) 7(4):255-66. doi:10.1038/nri2056
36. Rachel H, Chang-Chun L. Recent advances toward the development of inhibitors to attenuate tumor metastasis via the interruption of lectin-ligand interactions. In: Derek H, editor. Advances in Carbohydrate Chemistry and Biochemistry. Oxford: Academic Press (2013). p. 125-207
37. Magesh S, Ando H, Tsubata T, Ishida H, Kiso M. High-affinity ligands of siglec receptors and their therapeutic potentials. Curr Med Chem (2011) 18(23):3537-50. doi:10.2174/092986711796642580
38. Pillai S, Netravali IA, Cariappa A, Mattoo H. Siglecs and immune regulation. Annu Rev Immunol (2012) 30(1):357-92. doi:10.1146/annurev-immunol-020711-075018
39. Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol (2014) 14(10):653-66. doi:10.1038/nri3737
40. Merli M, Ferrario A, Maffioli M, Arcaini L, Passamonti F. Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma. Expert Opin Investig Drugs (2015) 24(7):897-912. doi:10.1517/13543784.2015.1038342
41. Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, Démoulins T, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest (2014) 124(4):1810-20. doi:10.1172/JCI65899
42. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia (2004) 19(2):176-82. doi:10.1038/sj.leu.2403598
43. Takamiya R, Ohtsubo K, Takamatsu S, Taniguchi N, Angata T. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology (2013) 23(2):178-87. doi:10.1093/glycob/cws139
44. Swanson BJ, McDermott KM, Singh PK, Eggers JP, Crocker PR, Hollingsworth MA. MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Res (2007) 67(21):10222-9. doi:10.1158/0008-5472.can-06-2483
45. Mitra N, Banda K, Altheide TK, Schaffer L, Johnson-Pais TL, Beuten J, et al. SIGLEC12, a human-specific segregating (Pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas. J Biol Chem (2011) 286(26):23003-11. doi:10.1074/jbc.M111.244152
46. Cummings RD, McEver RP. C-type lectins. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors. Essentials of Glycobiology. Chapter 31. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press (2009). Available from: http://www.ncbi.nlm.nih.gov/books/NBK1943/
47. Chen M, Geng J-G. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz) (2006) 54(2):75-84. doi:10.1007/s00005-006-0010-6
48. Barthel SR, Gavino JD, Descheny L, Dimitroff CJ. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets (2007) 11(11):1473-91. doi:10.1517/14728222.11.11.1473
49. Chen ZP, Jing YMS, Song BMS, Han YMS, Chu YP. Chemically modified heparin inhibits in vitro L-selectin-mediated human ovarian carcinoma cell adhesion. Int J Gynecol Cancer (2009) 19(4):540-6. doi:10.1111/IGC.0b013e3181a44bc8
50. Vasta GR. Galectins as pattern recognition receptors: structure, function, and evolution. Adv Exp Med Biol (2012) 946:21-36. doi:10.1007/978-1-4614-0106-3_2
51. Huflejt M, Leffler H. Galectin-4 in normal tissues and cancer. Glycoconj J (2003) 20(4):247-55. doi:10.1023/B:GLYC.0000025819.54723.a0
52. Oka T, Murakami S, Arata Y, Hirabayashi J, Kasai K-I, Wada Y, et al. Identification and cloning of rat galectin-2: expression is predominantly in epithelial cells of the stomach. Arch Biochem Biophys (1999) 361(2):195-201. doi:10.1006/abbi.1998.0968
53. Madsen P, Rasmussen HH, Flint T, Gromov P, Kruse TA, Honoré B, et al. Cloning, expression, and chromosome mapping of human galectin-7. J Biol Chem (1995) 270(11):5823-9. doi:10.1074/jbc.270.11.5823
54. Dyer KD, Rosenberg HF. Eosinophil charcot-leyden crystal protein binds to beta-galactoside sugars. Life Sci (1996) 58(23):2073-82. doi:10.1016/0024-3205(96)00201-9
55. Yang R-Y, Hsu DK, Yu L, Chen H-Y, Liu F-T. Galectin-12 is required for adipogenic signaling and adipocyte differentiation. J Biol Chem (2004) 279(28):29761-6. doi:10.1074/jbc.M401303200
56. Hotta K, Funahashi T, Matsukawa Y, Takahashi M, Nishizawa H, Kishida K, et al. Galectin-12, an adipose-expressed galectin-like molecule possessing apoptosis-inducing activity. J Biol Chem (2001) 276(36):34089-97. doi:10.1074/jbc.M105097200
57. Rabinovich Gabriel A, Croci Diego O. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity (2012) 36(3):322-35. doi:10.1016/j.immuni.2012.03.004
58. Salatino M, Rabinovich GA. Fine-tuning antitumor responses through the control of galectin-glycan interactions: an overview. In: Cuturi CM, Anegon I, editors. Suppression and Regulation of Immune Responses: Methods and Protocols. Totowa, NJ: Humana Press (2011). p. 355-74
59. Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene (2001) 20:7486-93. doi:10.1038/sj.onc.1204950
60. Harazono Y, Kho DH, Balan V, Nakajima K, Zhang T, Hogan V, et al. Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells. Oncotarget (2014) 5(20):9992-10001. doi:10.18632/oncotarget.2486
61. Kopitz J, von Reitzenstein C, André S, Kaltner H, Uhl J, Ehemann V, et al. Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J Biol Chem (2001) 276(38):35917-23. doi:10.1074/jbc.M105135200
62. Markowska AI, Liu F-T, Panjwani N. Galectin-3 is an important mediator of VEGF-and bFGF-mediated angiogenic response. J Exp Med (2010) 207(9):1981-93. doi:10.1084/jem.20090121
63. Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Deltour L, et al. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res (2010) 70(15):6216-24. doi:10.1158/0008-5472.can-09-4150
64. Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, Méndez-Huergo SP, et al. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res (2013) 73(3):1107-17. doi:10.1158/0008-5472.CAN-12-2418
65. Hittelet A, Legendre H, Nagy N, Bronckart Y, Pector J-C, Salmon I, et al. Upregulation of galectins-1 and-3 in human colon cancer and their role in regulating cell migration. Int J Cancer (2003) 103(3):370-9. doi:10.1002/ijc.10843
66. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell (2004) 5(3):241-51. doi:10.1016/S1535-6108(04)00024-8
67. Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD, et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol (2007) 8(8):825-34. doi:10.1038/ni1482
68. Stowell SR, Qian Y, Karmakar S, Koyama NS, Dias-Baruffi M, Leffler H, et al. Differential roles of galectin-1 and galectin-3 in regulating leukocyte viability and cytokine secretion. J Immunol (2008) 180(5):3091-102. doi:10.4049/jimmunol.180.5.3091
69. Liu F-T, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer (2005) 5(1):29-41. doi:10.1038/nrc1527
70. Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature (1995) 378(6558):736-9. doi:10.1038/378736a0
71. Ilarregui JM, Croci DO, Bianco GA, Toscano MA, Salatino M, Vermeulen ME, et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol (2009) 10(9):981-91. doi:10.1038/ni.1772
72. Thiemann S, Man JH, Chang MH, Lee B, Baum LG. Galectin-1 regulates tissue exit of specific dendritic cell populations. J Biol Chem (2015) 290:22662-77. doi:10.1074/jbc.M115.644799
73. Kuo P-L, Hung J-Y, Huang S-K, Chou S-H, Cheng D-E, Jong Y-J, et al. Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. J Immunol (2011) 186(3):1521-30. doi:10.4049/jimmunol.1002940
74. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev (2014) 40(2):307-19. doi:10.1016/j.ctrv.2013.07.007
75. Ito K, Stannard K, Gabutero E, Clark A, Neo S-Y, Onturk S, et al. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev (2012) 31(3-4):763-78. doi:10.1007/s10555-012-9388-2
76. Belanis L, Plowman SJ, Rotblat B, Hancock JF, Kloog Y. Galectin-1 is a novel structural component and a major regulator of H-Ras nanoclusters. Mol Biol Cell (2008) 19(4):1404-14. doi:10.1091/mbc.E07-10-1053
77. Nakahara S, Oka N, Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis (2005) 10(2):267-75. doi:10.1007/s10495-005-0801-y
78. Raz A, Zhu D, Hogan V, Shah N, Raz T, Karkash R, et al. Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer (1990) 46(5):871-7. doi:10.1002/ijc.2910460520
79. Oliveira JTD, Ribeiro C, Gärtner F. Role of galectin-3 in cancer metastasis. Glycobiol Insights (2015) 5:1-13. doi:10.4137/GBI.S13916
80. Fukumori T, Kanayama H-O, Raz A. The role of galectin-3 in cancer drug resistance. Drug Resist Updat (2007) 10(3):101-8. doi:10.1016/j.drup.2007.04.001
81. Glinsky VV, Glinsky GV, Rittenhouse-Olson K, Huflejt ME, Glinskii OV, Deutscher SL, et al. The role of thomsen-friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res (2001) 61(12):4851-7
82. Demotte N, Stroobant V, Courtoy PJ, Van Der Smissen P, Colau D, Luescher IF, et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity (2008) 28(3):414-24. doi:10.1016/j.immuni.2008.01.011
83. Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka N, Habuchi T, Horikawa Y, et al. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J (2011) 30(15):3173-85. doi:10.1038/emboj.2011.215
84. Park GB, Kim D, Kim Y, Lee H, Kim CW, Hur DY. Silencing of galectin-3 represses osteosarcoma cell migration and invasion through inhibition of FAK/Src/Lyn activation and β-catenin expression and increases susceptibility to chemotherapeutic agents. Int J Oncol (2015) 46:185-94. doi:10.3892/ijo.2014.2721
85. Moon B-K, Lee YJ, Battle P, Jessup JM, Raz A, Kim H-RC. Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am J Pathol (2001) 159(3):1055-60. doi:10.1016/S0002-9440(10)61780-4
86. Harazono Y, Hyo Kho D, Balan V, Nakajima K, Hogan V, Raz A. Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling. Oncotarget (2015) 6(23):19592-604. doi:10.18632/oncotarget.4285
87. Harazono Y, Nakajima K, Raz A. Why anti-Bcl-2 clinical trials fail: a solution. Cancer Metastasis Rev (2014) 33(1):285-94. doi:10.1007/s10555-013-9450-8
88. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A (2001) 98(6):3352-7. doi:10.1073/pnas.061615598
89. Kozlowski EO, Pavao MSG, Borsig L. Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin. J Thromb Haemost (2011) 9(9):1807-15. doi:10.1111/j.1538-7836.2011.04401.x
90. Wang R, Huang J, Wei M, Zeng X. The synergy of 6-O-sulfation and N-or 3-O-sulfation of chitosan is required for efficient inhibition of P-selectin-mediated human melanoma A375 cell adhesion. Biosci Biotechnol Biochem (2010) 74(8):1697-700. doi:10.1271/bbb.100140
91. Perez-Castells J, Hernandez-Gay JJ, Denton RW, Tony KA, Mootoo DR, Jimenez-Barbero J. The conformational behaviour and P-selectin inhibition of fluorine-containing sialyl LeX glycomimetics. Org Biomol Chem (2007) 5(7):1087-92. doi:10.1039/B615752A
92. Shodai T, Suzuki J, Kudo S, Itoh S, Terada M, Fujita S, et al. Inhibition of P-selectin-mediated cell adhesion by a sulfated derivative of sialic acid. Biochem Biophys Res Commun (2003) 312(3):787-93. doi:10.1016/j.bbrc.2003.10.188
93. Gouge-Ibert V, Pierry C, Poulain F, Serre A-L, Largeau C, Escriou V, et al. Synthesis of fluorinated C-mannopeptides as sialyl Lewisx mimics for E-and P-selectin inhibition. Bioorg Med Chem Lett (2010) 20(6):1957-60. doi:10.1016/j.bmcl.2010.01.141
94. Filser C, Kowalczyk D, Jones C, Wild MK, Ipe U, Vestweber D, et al. Synthetic glycopeptides from the E-selectin ligand 1 with varied sialyl Lewisx structure as cell-adhesion inhibitors of E-selectin. Angew Chem Int Ed (2007) 46(12):2108-11. doi:10.1002/anie.200604442
95. Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest (2001) 108(2):169-73. doi:10.1172/JCI200113530
96. Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol (2012) 2012:10. doi:10.1155/2012/676731
97. Hostettler N, Naggi A, Torri G, Ishai-Michaeli R, Casu B, Vlodavsky I, et al. P-selectin-and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J (2007) 21(13):3562-72. doi:10.1096/fj.07-8450com
98. Kragh M, Binderup L, Vig Hjarnaa P, Bramm E, Johansen KB, Frimundt Petersen C. Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. Oncol Rep (2005) 14:99-104. doi:10.3892/or.14.1.99
99. Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost (2009) 102(8):258-67. doi:10.1160/TH08-12-0832
100. Belting M. Glycosaminoglycans in cancer treatment. Thromb Res (2014) 133(Suppl 2):S95-101. doi:10.1016/S0049-3848(14)50016-3
101. Denton RW, Cheng X, Tony KA, Dilhas A, Hernández JJ, Canales A, et al. C-disaccharides as probes for carbohydrate recognition-investigation of the conformational requirements for binding of disaccharide mimetics of sialyl Lewis X. European J Org Chem (2007) 2007(4):645-54. doi:10.1002/ejoc.200600825
102. Nicoll G, Avril T, Lock K, Furukawa K, Bovin N, Crocker PR. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and-independent mechanisms. Eur J Immunol (2003) 33(6):1642-8. doi:10.1002/eji.200323693
103. Attrill H, Takazawa H, Witt S, Kelm S, Isecke R, Brossmer R, et al. The structure of siglec-7 in complex with sialosides: leads for rational structure-based inhibitor design. Biochem J (2006) 397(2):271-8. doi:10.1042/bj20060103
104. Kelm S, Gerlach J, Brossmer R, Danzer C-P, Nitschke L. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J Exp Med (2002) 195(9):1207-13. doi:10.1084/jem.20011783
105. Chen WC, Completo GC, Sigal DS, Crocker PR, Saven A, Paulson JC. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood (2010) 115(23):4778-86. doi:10.1182/blood-2009-12-257386
106. Kelm S, Madge P, Islam T, Bennett R, Koliwer-Brandl H, Waespy M, et al. C-4 modified sialosides enhance binding to siglec-2 (CD22): towards potent Siglec inhibitors for immunoglycotherapy. Angew Chem Int Ed (2013) 52(13):3616-20. doi:10.1002/anie.201207267
107. Blanchard H, Yu X, Collins PM, Bum-Erdene K. Galectin-3 inhibitors: a patent review (2008-present). Expert Opin Ther Pat (2014) 24(10):1053-65. doi:10.1517/13543776.2014.947961
108. Blanchard H, Bum-Erdene K, Hugo MW. Inhibitors of galectins and implications for structure-based design of galectin-specific therapeutics. Aust J Chem (2014) 67(12):1763-79. doi:10.1071/CH14362
109. Tellez-Sanz R, Garcia-Fuentes L, Vargas-Berenguel A. Human galectin-3 selective and high affinity inhibitors. Present state and future perspectives. Curr Med Chem (2013) 20(24):2979-90. doi:10.2174/09298673113209990163
110. Ingrassia L, Nshimyumukiza P, Dewelle J, Lefranc F, Wlodarczak L, Thomas S, et al. A lactosylated steroid contributes in vivo therapeutic benefits in experimental models of mouse lymphoma and human glioblastoma. J Med Chem (2006) 49(5):1800-7. doi:10.1021/jm050971v
111. Iurisci IDA, Cumashi A, Sherman AA, Tsvetkov YE, Tinari N, Piccolo E, et al. Synthetic inhibitors of galectin-1 and-3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res (2009) 29(1):403-10
112. Ito K, Ralph S. Inhibiting galectin-1 reduces murine lung metastasis with increased CD4+ and CD8+ T cells and reduced cancer cell adherence. Clin Exp Metastasis (2012) 29(6):561-72. doi:10.1007/s10585-012-9471-7
113. Leffler H, Nilsson UJ. Low-molecular weight inhibitors of galectins. In: Klyosov AA, Traber PG, editors. Galectins and Disease Implications for Targeted Therapeutics. Washington, DC: Oxford University Press (2012). p. 47-59
114. Lin C-I, Whang EE, Donner DB, Jiang X, Price BD, Carothers AM, et al. Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res (2009) 7(10):1655-62. doi:10.1158/1541-7786.MCR-09-0274
115. Öberg CT, Noresson A-L, Leffler H, Nilsson UJ. Synthesis of 3-amido-3-deoxy-β-d-talopyranosides: all-cis-substituted pyranosides as lectin inhibitors. Tetrahedron (2011) 67(47):9164-72. doi:10.1016/j.tet.2011.09.098
116. Glinskii OV, Sud S, Mossine VV, Mawhinney TP, Anthony DC, Glinsky GV, et al. Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-l-leucine. Neoplasia (2012) 14(1):65-73. doi:10.1593/neo.111544
117. Glinsky VV, Kiriakova G, Glinskii OV, Mossine VV, Mawhinney TP, Turk JR, et al. Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo. Neoplasia (2009) 11(9):901-9. doi:10.1593/neo.09594
118. Glinsky GV, Price JE, Glinsky VV, Mossine VV, Kiriakova G, Metcalf JB. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines. Cancer Res (1996) 56(23):5319-24
119. Rabinovich GA, Cumashi A, Bianco GA, Ciavardelli D, Iurisci I, D'Egidio M, et al. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology (2006) 16(3):210-20. doi:10.1093/glycob/cwj056
120. Zhang W, Xu P, Zhang H. Pectin in cancer therapy: a review. Trends Food Sci Technol (2015) 44(2):258-71. doi:10.1016/j.tifs.2015.04.001
121. Jiang J, Eliaz I, Sliva D. Synergistic and additive effects of modified citrus pectin with two polybotanical compounds, in the suppression of invasive behavior of human breast and prostate cancer cells. Integr Cancer Ther (2013) 12(2):145-52. doi:10.1177/1534735412442369
122. Jun Y, Katz A. PectaSol-C modified citrus pectin induces apoptosis and inhibition of proliferation in human and mouse androgen-dependent and-independent prostate cancer cells. Integr Cancer Ther (2010) 9(2):197-203. doi:10.1177/1534735410369672
123. Jackson CL, Dreaden TM, Theobald LK, Tran NM, Beal TL, Eid M, et al. Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure. Glycobiology (2007) 17(8):805-19. doi:10.1093/glycob/cwm054
124. Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis (2003) 6(4):301-4. doi:10.1038/sj.pcan.4500679
125. Grous JJ, Redfern CH, Mahadevanm D, Schindler J. GCS-100, a galectin-3 antagonist, in refractory solid tumors: a phase I study. 2006 ASCO Annual Meeting Proceedings. June 2-6. Atlanta (2006). 13023
126. Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res (2005) 65(18):8350-8. doi:10.1158/0008-5472.CAN-05-0163
127. Zomer E, Traber PG, Klyosov AA, Chekhova E. Google Patents. Composition of Novel Carbohydrate Drug for Treatment of Human Diseases. (2013)
128. Klyosov A, Zomer E, Platt D. DAVANAT (GM-CT-01) and colon cancer: preclinical and clinical (phase I and II) studies. In: Klyosov AA, editor. Glycobiology and Drug Design. Washington, DC: Oxford University Press (2012). p. 89-130
129. Newton-Northup J, Dickerson M, Ma L, Besch-Williford C, Deutscher S. Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide. Clin Exp Metastasis (2013) 30(2):119-32. doi:10.1007/s10585-012-9516-y
130. Deutscher SL, Figueroa SD, Kumar SR. Tumor targeting and SPECT imaging properties of an 111In-labeled galectin-3 binding peptide in prostate carcinoma. Nucl Med Biol (2009) 36(2):137-46. doi:10.1016/j.nucmedbio.2008.10.015
131. Dings RPM, van der Schaft DWJ, Hargittai B, Haseman J, Griffioen AW, Mayo KH. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett (2003) 194(1):55-66. doi:10.1016/S0304-3835(03)00015-6
132. Mayo KH, Dings RPM, Flader C, Nesmelova I, Hargittai B, van der Schaft DWJ, et al. Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J Biol Chem (2003) 278(46):45746-52. doi:10.1074/jbc.M308608200
133. Zucchetti M, Bonezzi K, Frapolli R, Sala F, Borsotti P, Zangarini M, et al. Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemother Pharmacol (2013) 72(4):879-87. doi:10.1007/s00280-013-2270-2
134. Dings RPM, Chen X, Hellebrekers DMEI, van Eijk LI, Zhang Y, Hoye TR, et al. Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst (2006) 98(13):932-6. doi:10.1093/jnci/djj247
135. Cagnoni AJ, Kovensky J, Uhrig ML. Design and synthesis of hydrolytically stable multivalent ligands bearing thiodigalactoside analogues for peanut lectin and human galectin-3 binding. J Org Chem (2014) 79(14):6456-67. doi:10.1021/jo500883v
136. Cumpstey I, Salomonsson E, Sundin A, Leffler H, Nilsson UJ. Double affinity amplification of galectin-ligand interactions through arginine-arene interactions: synthetic, thermodynamic, and computational studies with aromatic diamido thiodigalactosides. Chemistry (2008) 14(14):4233-45. doi:10.1002/chem.200701932
137. Ito K, Scott S, Cutler S, Dong L-F, Neuzil J, Blanchard H, et al. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis (2011) 14(3):293-307. doi:10.1007/s10456-011-9213-5
138. Öberg CT, Blanchard H, Leffler H, Nilsson UJ. Protein subtype-targeting through ligand epimerization: talose-selectivity of galectin-4 and galectin-8. Bioorg Med Chem Lett (2008) 18(13):3691-4. doi:10.1016/j.bmcl.2008.05.066
139. Leclere L, Van Cutsem P, Michiels C. Anti-cancer activities of pH-or heat-modified pectin. Front Pharmacol (2013) 4:128. doi:10.3389/fphar.2013.00128
140. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst (2002) 94(24):1854-62. doi:10.1093/jnci/94.24.1854
141. Pienta KJ, Nailk H, Akhtar A, Yamazaki K, Replogle TS, Lehr J, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst (1995) 87(5):348-53. doi:10.1093/jnci/87.5.348
142. Platt D, Raz A. Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst (1992) 84(6):438-42. doi:10.1093/jnci/84.6.438
143. Menachem A, Bodner O, Pastor J, Raz A, Kloog Y. Inhibition of malignant thyroid carcinoma cell proliferation by Ras and galectin-3 inhibitors. Cell Death Discov (2015) 1:15047. doi:10.1038/cddiscovery.2015.47
144. Demotte N, Wieërs G, Van Der Smissen P, Moser M, Schmidt C, Thielemans K, et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res (2010) 70(19):7476-88. doi:10.1158/0008-5472.CAN-10-0761
145. Demotte N, Bigirimana R, Wieërs G, Stroobant V, Squifflet J-L, Carrasco J, et al. A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes. Clin Cancer Res (2014) 20(7):1823-33. doi:10.1158/1078-0432.CCR-13-2459
146. Cotter F, Smith DA, Boyd TE, Richards DA, Alemany C, Loesch D, et al. Single-agent activity of GCS-100, a first-in-class galectin-3 antagonist, in elderly patients with relapsed chronic lymphocytic leukemia. 2009 ASCO Annual Meeting Proceedings. May 29-June 2. Orlando (2009). 7006
147. Zomer E, Klyosov AA, Platt D. Development of a galactomannan polysaccharide as a vehicle to improve the efficacy of chemotherapeutics. In: Klyosov AA, editor. Glycobiology and Drug Design. Washington, DC: Oxford University Press (2012). p. 69-87
148. Miller MC, Klyosov A, Platt D, Mayo KH. Using pulse field gradient NMR diffusion measurements to define molecular size distributions in glycan preparations. Carbohydr Res (2009) 344(10):1205-12. doi:10.1016/j.carres.2009.04.010
149. Miller MC, Klyosov A, Mayo KH. The α-galactomannan davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain. Glycobiology (2009) 19(9):1034-45. doi:10.1093/glycob/cwp084
150. Zou J, Glinsky VV, Landon LA, Matthews L, Deutscher SL. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis (2005) 26(2):309-18. doi:10.1093/carcin/bgh329
151. Yang Y, Li L, Zhou Z, Yang Q, Liu C, Huang Y. Targeting prostate carcinoma by G3-C12 peptide conjugated N-(2-Hydroxypropyl)methacrylamide copolymers. Mol Pharm (2014) 11(10):3251-60. doi:10.1021/mp500083u
152. Yang Y, Zhou Z, He S, Fan T, Jin Y, Zhu X, et al. Treatment of prostate carcinoma with (Galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates. Biomaterials (2012) 33(7):2260-71. doi:10.1016/j.biomaterials.2011.12.007
153. Sun W, Li L, Yang Q, Shan W, Zhang Z, Huang Y. G3-C12 peptide reverses galectin-3 from foe to friend for active targeting cancer treatment. Mol Pharm (2015) 12(11):4124-36. doi:10.1021/acs.molpharmaceut.5b00568
154. Balan V, Nangia-Makker P, Raz A. Galectins as cancer biomarkers. Cancers (Basel) (2010) 2(2):592. doi:10.3390/cancers2020592
155. Wang JB, Wang MD, Li EX, Dong DF. Advances and prospects of anginex as a promising anti-angiogenesis and anti-tumor agent. Peptides (2012) 38(2):457-62. doi:10.1016/j.peptides.2012.09.007
156. Mayo KH. From carbohydrate to peptidomimetic inhibitors of galectins. In: Klyosov AA, Traber PG, editors. Galectins and Disease Implications for Targeted Therapeutics. Washington, DC: Oxford University Press (2012). p. 61-77
157. Griffioen AW, van der Schaft DW, Barendsz-Janson AF, Cox A, Struijker Boudier HA, Hillen HF, et al. Anginex, a designed peptide that inhibits angiogenesis. Biochem J (2001) 354(Pt 2):233-42. doi:10.1042/bj3540233
158. Brandwijk RJMGE, Dings RPM, van der Linden E, Mayo KH, Thijssen VLJL, Griffioen AW. Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun (2006) 349(3):1073-8. doi:10.1016/j.bbrc.2006.08.154
159. Salomonsson E, Thijssen VL, Griffioen AW, Nilsson UJ, Leffler H. The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins. J Biol Chem (2011) 286(16):13801-4. doi:10.1074/jbc.C111.229096
160. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Rabinovich GA, Bieche I, et al. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis. Eur J Cancer (2014) 50(14):2463-77. doi:10.1016/j.ejca.2014.06.015
161. Rezai K, Durand S, Lachaux N, Raymond E, Herait P, Lokiec F. OTX008 pharmacokinetics (PK) during the first-in-man phase I study in patients with advanced solid tumors. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research April 6-10, 2013. Washington, DC (2013)
162. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12(4):252-64. doi:10.1038/nrc3239
163. Böcker S, Laaf D, Elling L. Galectin binding to neo-glycoproteins: LacDiNAc conjugated BSA as ligand for human galectin-3. Biomolecules (2015) 5(3):1671. doi:10.3390/biom5031671
164. Cedeno-Laurent F, Opperman M, Barthel SR, Hays D, Schatton T, Zhan Q, et al. Metabolic inhibition of galectin-1-binding carbohydrates accentuates anti-tumor immunity. J Invest Dermatol (2012) 132(2):410-20. doi:10.1038/jid.2011.335
165. Gao X, Zhi Y, Zhang T, Xue H, Wang X, Foday A, et al. Analysis of the neutral polysaccharide fraction of MCP and its inhibitory activity on galectin-3. Glycoconj J (2012) 29(4):159-65. doi:10.1007/s10719-012-9382-5
166. Martín-Satué M, Marrugat R, Cancelas JA, Blanco J. Enhanced expression of a(1,3)-fucosyltransferase genes correlates with E-selectin-mediated adhesion and metastatic potential of human lung adenocarcinoma cells. Cancer Res (1998) 58(7):1544-50
167. Brodt P, Fallavollita L, Bresalier RS, Meterissian S, Norton CR, Wolitzky BA. Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int J Cancer (1997) 71(4):612-9. doi:10.1002/(SICI)1097-0215(19970516)71:4<612:AID-IJC17>3.0.CO;2-D
168. Eppihimer MJ, Schaub RG. Soluble P-selectin antagonist mediates rolling velocity and adhesion of leukocytes in acutely inflamed venules. Microcirculation (2001) 8(1):15-24. doi:10.1111/j.1549-8719.2001.tb00154.x
169. Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL, Nguyen DD, et al. Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecol Oncol (2014) 135(3):573-9. doi:10.1016/j.ygyno.2014.09.021
170. Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med (2012) 209(11):1985-2000. doi:10.1084/jem.20111665
171. Ouyang J, Juszczynski P, Rodig SJ, Green MR, Donnell E, Currie T, et al. Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood (2011) 117(16):4315-22. doi:10.1182/blood-2010-11-320481